Structure Therapeutics (NASDAQ:GPCR) Now Covered by Morgan Stanley

Morgan Stanley assumed coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note published on Monday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $118.00 price objective on the stock.

Several other brokerages have also issued reports on GPCR. Cantor Fitzgerald reaffirmed an overweight rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 16th. JMP Securities decreased their price objective on Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating for the company in a report on Friday, August 9th. Finally, BMO Capital Markets lifted their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the stock an outperform rating in a report on Friday, June 7th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus target price of $88.33.

Structure Therapeutics Trading Down 1.0 %

Shares of NASDAQ:GPCR opened at $41.53 on Monday. The stock’s fifty day simple moving average is $37.98 and its two-hundred day simple moving average is $39.72. Structure Therapeutics has a 1-year low of $26.61 and a 1-year high of $75.02. The stock has a market cap of $1.94 billion, a PE ratio of -54.71 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, sell-side analysts forecast that Structure Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Teachers Retirement System of The State of Kentucky boosted its stake in Structure Therapeutics by 28.5% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 17,651 shares of the company’s stock worth $693,000 after purchasing an additional 3,918 shares during the period. Perceptive Advisors LLC bought a new position in Structure Therapeutics in the 2nd quarter worth about $1,369,000. Quarry LP bought a new position in Structure Therapeutics in the 2nd quarter worth about $79,000. Driehaus Capital Management LLC boosted its position in shares of Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock valued at $101,204,000 after acquiring an additional 86,833 shares during the last quarter. Finally, Blue Owl Capital Holdings LP bought a new stake in shares of Structure Therapeutics during the 2nd quarter valued at about $2,160,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.